Institute of Molecular Biology Inc. has signed an agreement givingKendall International exclusive North American marketing anddistribution rights to Molecular Biology's combination growth factorsfor treatment of chronic skin ulcers.Tom Tully, president of the Worcester, Mass.-based Institute ofMolecular Biology, said financial terms were not disclosed. The dealalso gives Kendall, of Mansfield, Mass., a minority equity position inthe privately-held Molecular Biology. Tully also declined to releasethose details."This is a very important milestone for us," Tully said. "Kendall is avery attractive marketing partner for our product once it is approved."Molecular Biology has developed combinations of naturally occurringgrowth factors for repair and regeneration of soft and hard humantissue.Tully said the company currently has a Phase I/II trial under way withits combination growth factor technology. Those studies are expectedto be complete in the next couple of months.Kendall manufactures and markets a variety of wound care products._ Charles Craig082594
(c) 1997 American Health Consultants. All rights reserved.